This trial will investigate the effects of the SGLT2 inhibitor dapagliflozin compared with placebo on the incidence of kidney failure, heart failure and mortality, as well as on safety, in patients with severely impaired kidney function, on dialysis or living with a kidney transplant. Here, SLC5A2 is linked to kidney failure.